What is the global impact of malaria as of 2022?

In 2022, malaria affected an estimated 249 million people worldwide and caused 608,000 deaths. Malaria is a mosquito-borne infectious disease that poses a significant global health challenge.

What is the first approved vaccine for malaria, and what is its brand name?

The first malaria vaccine to receive public approval is RTS,S, which is marketed under the brand name Mosquirix. This marks a significant milestone in the fight against this disease.

How many children had received the RTS,S vaccine by April 2023?

By April 2023, approximately 1.5 million children residing in areas with moderate to high malaria transmission had received at least one dose of the RTS,S vaccine.

What is the recommended dosage schedule for the RTS,S vaccine in infants?

The RTS,S vaccine requires a minimum of three doses for infants by the age of two. An additional fourth dose is administered to extend the protection period for another one to two years.

What is the approximate reduction in hospital admissions for severe malaria achieved by the RTS,S vaccine?

The RTS,S vaccine has demonstrated the ability to reduce hospital admissions resulting from severe malaria by about 30%, contributing to better health outcomes for children.

Which malaria vaccine is considered the most effective based on initial trials, and what is its efficacy rate?

The R21/Matrix-M vaccine has shown the highest efficacy in initial trials, achieving a 77% rate. This makes it a highly promising candidate for malaria prevention.

Does the R21/Matrix-M vaccine meet the World Health Organization's efficacy goal for malaria vaccines?

Yes, the R21/Matrix-M vaccine is the first malaria vaccine candidate to meet the World Health Organization's target efficacy of at least 75%.

Which countries were the first to approve the R21/Matrix-M vaccine for use in children?

Ghana was the first country to approve the R21 vaccine in April 2023 for children aged five months to three years. Nigeria subsequently provided provisional approval.

Who developed the RTS,S malaria vaccine?

The RTS,S vaccine was developed through a collaborative effort involving PATH Malaria Vaccine Initiative (MVI) and GlaxoSmithKline (GSK), with crucial support from the Bill and Melinda Gates Foundation.

How does the RTS,S vaccine aim to prevent malaria infection?

The vaccine works by stimulating the immune system to produce antibodies that block the malaria parasite from invading liver cells (hepatocytes). It also aims to elicit a cellular immune response to eliminate infected liver cells.

What challenge did the RTS,S vaccine face during its trial stages, and how was it addressed?

A significant challenge during the RTS,S trials was its poor immunogenicity. Researchers addressed this by fusing the CSP antigen with the hepatitis B virus surface antigen, creating a more potent and immunogenic vaccine formulation.

What were the efficacy results of the RTS,S vaccine in clinical trials regarding children and infants?

Clinical trials indicated that RTS,S/AS01 reduced malaria cases by approximately 50% in young children and about 25% in infants. However, the vaccine's efficacy waned over time, and protection against severe malaria was significantly reduced without a booster dose.

What is the World Health Organization's (WHO) current stance on the RTS,S vaccine?

The WHO endorsed RTS,S for widespread use in children in October 2021, marking the first such recommendation for a malaria vaccine. It was subsequently prequalified by the WHO in July 2022.

What is the R21/Matrix-M vaccine and who were the key developers?

R21/Matrix-M is a highly effective malaria vaccine candidate developed through a collaboration involving the Jenner Institute at the University of Oxford, the Kenya Medical Research Institute, the London School of Hygiene and Tropical Medicine, Novavax, and the Serum Institute of India.

What adjuvant is used in the R21/Matrix-M vaccine?

The R21/Matrix-M vaccine incorporates the Matrix-M adjuvant, which is also employed in the Novavax COVID-19 vaccine, enhancing the immune response.

What was the efficacy of the R21/Matrix-M vaccine in a phase III trial involving children?

A phase III trial involving 4,800 children across four African countries demonstrated that the R21/Matrix-M vaccine achieved 74% efficacy against severe malaria episodes.

What is the planned annual production capacity for the R21/Matrix-M vaccine?

The Serum Institute of India is preparing to produce between 100 and 200 million doses of the R21/Matrix-M vaccine per year, with a new factory being constructed in Accra, Ghana.

What are the two primary types of immune responses that malaria vaccines aim to induce?

Malaria vaccines aim to elicit either 'anti-parasitic immunity,' which involves antibody and cell-mediated responses to directly target the parasite, or 'anti-toxic immunity,' which focuses on mitigating the symptoms caused by the parasite's by-products.

Why is parasite diversity a critical consideration in the development of malaria vaccines?

The malaria parasite, particularly *P. falciparum*, exhibits rapid evolutionary change and high replication rates. This genetic diversity can lead to the development of resistance against vaccines, potentially diminishing their effectiveness over time.

What are the potential targets within the malaria parasite's lifecycle for vaccine development?

Vaccine development can target various stages of the malaria parasite's lifecycle, including the sporozoite stage (to prevent liver cell invasion), the hepatozoite stage, the asexual erythrocytic stage (to block invasion or neutralize toxins), and the gametocyte stage (to prevent transmission).

What is the purpose of a transmission-blocking vaccine for malaria?

A transmission-blocking vaccine targets the sexual stage of the malaria parasite. Its goal is to prevent the parasite from developing within the mosquito vector, thereby interrupting the transmission cycle from mosquitoes to humans.

What is the WHO's classification of the malaria vaccine on its List of Essential Medicines?

The malaria vaccine is recognized by the World Health Organization and is included on its List of Essential Medicines, highlighting its critical role in global public health.

What is the Matrix-M adjuvant, and in which other vaccine is it used?

Matrix-M is an adjuvant utilized in the R21/Matrix-M malaria vaccine. It is also employed in the Novavax COVID-19 vaccine to enhance the immune response.

What was the efficacy of the RTS,S vaccine after four years, and what was the impact of a booster dose?

After four years, RTS,S showed a 36% reduction in malaria cases among children who received three doses plus a booster. However, the efficacy against severe malaria was negligible if the booster dose was missed.

What is the potential synergy mentioned for the PfSEA-1 vaccine candidate?

The PfSEA-1 vaccine candidate works by blocking the schizont's exit from red blood cells. This mechanism may offer synergistic benefits when combined with vaccines targeting other stages of the malaria lifecycle, such as those preventing liver or red blood cell invasion.

What is the significance of the Duffy binding protein (DBP) and DARC in *Plasmodium vivax* vaccine research?

The Duffy binding protein (DBP) and the Duffy antigen receptor for chemokines (DARC) are crucial for *Plasmodium vivax*'s invasion of red blood cells. Developing antibodies that interfere with the binding between DBP and DARC is a key strategy for creating vaccines against this malaria species.

What is the primary objective of a Type 1 malaria vaccine?

A Type 1 malaria vaccine is designed for regions with high malaria transmission, such as sub-Saharan Africa. Its main goal is to significantly reduce the incidence of severe malaria cases and deaths among infants and young children.

What is the primary objective of a Type 2 malaria vaccine?

A Type 2 malaria vaccine, often termed a 'travelers' vaccine,' aims to provide complete protection against all clinical symptoms of malaria for individuals who have no prior exposure to the parasite.

What was the outcome of the largest placebo-controlled randomized trial for the SPf66 vaccine in Southeast Asia?

The largest placebo-controlled randomized trial conducted for the SPf66 vaccine in Southeast Asia found it to be ineffective, showing no protective benefit, which led to its discontinuation.

What is the potential role of targeting protein kinases in malaria vaccine development?

Protein kinases are present throughout the malaria parasite's lifecycle, making them a potential target for vaccine development. However, creating a practical vaccine targeting these enzymes is anticipated to be a lengthy process.

What is the significance of the PfRH5 antigen's low genetic diversity for vaccine development?

The PfRH5 antigen's limited genetic variation suggests it could be a reliable target for a malaria vaccine, potentially enabling the development of antibodies that neutralize multiple strains of the parasite effectively.

What role has the Bill & Melinda Gates Foundation played in malaria vaccine development?

The Bill & Melinda Gates Foundation has been a major financial supporter of malaria eradication initiatives, providing substantial funding that has been critical for the development of vaccines like RTS,S.

What is the ATC code assigned to the malaria vaccine Mosquirix?

The Anatomical Therapeutic Chemical (ATC) classification code for Mosquirix, the malaria vaccine, is J07XA01.

What are the regulatory classifications for Mosquirix in the European Union and other regions?

In the European Union, Mosquirix is classified as prescription-only (Rx-only). It has also received approval for use in countries like Ghana and Nigeria.

What is the CAS Registry Number associated with the malaria vaccine Mosquirix?

The Chemical Abstracts Service (CAS) Registry Number for Mosquirix is 149121-47-1.

Which specific Wikipedia article serves as the primary reference for detailed information on the RTS,S vaccine?

The primary reference for detailed information about the RTS,S vaccine is the Wikipedia article specifically titled 'RTS,S'.

What is the target disease for the R21/Matrix-M vaccine?

The R21/Matrix-M vaccine is designed to prevent malaria.

What classification does the R21/Matrix-M vaccine fall under?

R21/Matrix-M is classified as a protein subunit vaccine.

What is the function of the Malaria Atlas Project mentioned in the text?

The Malaria Atlas Project is a resource related to the epidemiology of malaria, providing data on the disease's distribution and patterns.

What is the significance of the WHO's endorsement of the R21/Matrix-M vaccine in October 2023?

The WHO's endorsement of R21/Matrix-M in October 2023, following its earlier recommendation and prequalification, signifies its recognized potential as a crucial tool for malaria prevention efforts globally.

What future malaria vaccine development is mentioned in relation to R21/Matrix-M?

A potential second-generation malaria vaccine, provisionally named RH5.1/Matrix-M, is under development. It targets the erythrocytic stage and is intended to be used in combination with R21/Matrix-M to achieve even greater efficacy.

What historical method involved using irradiated mosquitoes to induce immunity against malaria?

Historically, in the 1970s, humans were immunized against malaria by being bitten by mosquitoes that had been exposed to X-rays. This process attenuated the malaria parasites, allowing them to elicit an immune response without causing a full infection.

What is the purpose of using adjuvants like Matrix-M in malaria vaccines?

Adjuvants like Matrix-M are included in vaccines to enhance and strengthen the immune response generated by the vaccine's antigens, leading to more effective protection.

What was the efficacy of the RTS,S vaccine in preventing clinical malaria episodes in children after three doses plus a booster over three years?

Over a three-year period, three doses of RTS,S plus a booster reduced the risk of clinical malaria episodes by 26% in children, though it offered no significant protection against severe malaria.

What is the challenge with targeting the erythrocytic stage of the malaria parasite for vaccine development?

A key challenge in targeting the erythrocytic stage is that red blood cells, the cells infected during this phase, lack Major Histocompatibility Complex (MHC) molecules on their surface, complicating the immune system's recognition of infected cells.

What is the significance of the PfEMP1 protein in malaria immunity?

PfEMP1 is a variant surface antigen produced by *Plasmodium falciparum*. Antibodies generated against PfEMP1 have been identified as crucial for providing protective immunity against malaria, making it a significant target for vaccine research.

What is the potential benefit of combining different antigenic components in a malaria vaccine?

Combining multiple parasite antigens from different stages of the lifecycle can potentially create a synergistic or additive effect, increasing the overall immunity generated and reducing the likelihood of resistant parasite strains developing.

What is the role of the circumsporozoite protein (CSP) in the RTS,S vaccine?

The RTS,S vaccine utilizes the circumsporozoite protein (CSP) antigen from the pre-erythrocytic stage of the malaria parasite. This antigen is designed to trigger an immune response that prevents the parasite from infecting liver cells.

What is the status of a completely effective malaria vaccine?

As of the information provided, a completely effective malaria vaccine is not yet available, although several promising candidates are in development and some have received approval for specific uses.

What is the purpose of the 'fast track designation' granted to the PfSPZ vaccine by the FDA?

The fast track designation granted by the U.S. Food and Drug Administration (FDA) to the PfSPZ vaccine in September 2016 is intended to expedite the development and review process for potential new medicines that treat serious conditions.

Malaria Vaccine Wiki: Malaria Vaccine: A Scientific Expedition into Prevention

Dive in with Flashcard Learning!

When you are ready...
🎮 Play the Wiki2Web Clarity Challenge Game🎮

Understanding Malaria Vaccines

Global Health Imperative

Malaria, a mosquito-borne infectious disease, represents a significant global health challenge. In 2022 alone, it affected an estimated 249 million people across 85 endemic countries, leading to 608,000 deaths. The development of effective vaccines is crucial for controlling and potentially eradicating this disease.^[2]

The Goal of Immunization

A malaria vaccine aims to stimulate the human immune system to recognize and neutralize the malaria parasite, Plasmodium, at various stages of its complex lifecycle. This prevents infection or significantly reduces disease severity, thereby mitigating the substantial morbidity and mortality associated with malaria.

Essential Medicine Status

The significance of malaria vaccines is underscored by their inclusion on the World Health Organization's Model List of Essential Medicines. This recognition highlights their critical role in public health and accessibility for populations most affected by malaria.^[11]

Approved Malaria Vaccines

RTS,S/Mosquirix

RTS,S, marketed as Mosquirix, holds the distinction of being the first malaria vaccine approved for widespread use. Developed collaboratively by PATH Malaria Vaccine Initiative and GlaxoSmithKline (GSK), with support from the Bill & Melinda Gates Foundation, it targets the pre-erythrocytic stage of the Plasmodium falciparum parasite.^[1]

It requires a primary series of three doses in infants by age two, followed by a fourth booster dose to extend protection. Clinical trials indicate it reduces hospital admissions due to severe malaria by approximately 30%.^[4]

R21/Matrix-M

The R21/Matrix-M vaccine represents a significant advancement, demonstrating a 77% efficacy rate in initial trials, meeting the World Health Organization's target of at least 75% efficacy. Developed by a consortium including the University of Oxford, Kenya Medical Research Institute, and the Serum Institute of India, it utilizes the Matrix-M adjuvant.^[6]

Ghana was the first country to approve R21 for use in children aged five months to three years in April 2023, followed by Nigeria's provisional approval. The Serum Institute of India is scaling up production to meet global demand.^[9]^[10]

Deep Dive: RTS,S/Mosquirix

Mechanism of Action

RTS,S is a recombinant protein subunit vaccine. It incorporates the circumsporozoite protein (CSP) antigen from the pre-erythrocytic stage of Plasmodium falciparum, fused with a surface antigen from the Hepatitis B virus. This fusion enhances immunogenicity. The vaccine elicits antibodies that block the parasite from infecting hepatocytes and also induces a cellular response to destroy infected liver cells.^[12]

Clinical Trial Outcomes

Phase III trials indicated that RTS,S/AS01 provided modest protection, reducing clinical malaria cases by nearly 50% in young children and about 25% in infants after three doses. A booster dose improved efficacy, with a 36% reduction in cases over four years for those receiving the booster. However, protection wanes over time, particularly against severe malaria.^[15]

Deployment and Impact

Pilot vaccination programs commenced in Malawi, Ghana, and Kenya in 2019. By April 2023, approximately 1.5 million children had received at least one dose through routine immunization programs. UNICEF has secured contracts for millions of doses, with further rollout planned in several African nations.^[3]^[24]

Focus: R21/Matrix-M

Advanced Efficacy

R21/Matrix-M utilizes a similar CSP antigen structure to RTS,S but incorporates the Matrix-M adjuvant, which has shown promise in enhancing immune responses. Initial trials reported a 77% efficacy, significantly exceeding the WHO's benchmark and demonstrating higher antibody levels compared to RTS,S.^[6]

Promising Trial Data

Phase II trials reported 77% efficacy, with a booster dose maintaining high protection for at least two years. A Phase III trial involving 4,800 children across four African countries demonstrated a 74% efficacy against severe malaria episodes. Further data is under review by regulatory bodies.^[28]^[29]

Manufacturing and Approval

The R21 vaccine received approval from Ghana's Food and Drugs Authority in April 2023, with Nigeria following suit. The Serum Institute of India is establishing manufacturing capabilities, aiming for substantial annual production to support global distribution efforts.^[9]^[31]

Vaccine Development Strategies

Targeting the Parasite Lifecycle

The complex lifecycle of the malaria parasite, Plasmodium, offers multiple targets for vaccine development. Strategies focus on eliciting immune responses against different stages:

Pre-erythrocytic stage: Targets sporozoites before they infect liver cells or infected liver cells themselves. RTS,S and R21 are examples of this approach.
Erythrocytic stage: Targets the parasite within red blood cells, aiming to prevent multiplication or invasion. This is challenging due to the lack of MHC molecule expression on red blood cells.
Sexual stage (Gametocytes): Targets the parasite stages responsible for transmission to mosquitoes, acting as transmission-blocking vaccines.

Combinations of antigens from different stages are being explored for enhanced efficacy.^[33]

Key Antigens and Approaches

Research focuses on specific parasite proteins, such as the Circumsporozoite Protein (CSP) targeted by RTS,S and R21, and PfRH5, which appears to have low genetic diversity and is a target for neutralizing antibodies.^[49] Other targets include PfEMP1, crucial for immune evasion, and PfSEA-1, which inhibits parasite egress from red blood cells.^[52]^[56]

Challenges: Parasite Diversity and Resistance

Plasmodium species exhibit significant genetic diversity and a high replication rate, which can lead to the rapid evolution of drug resistance. This evolutionary capacity poses a challenge for vaccine development, as a vaccine must ideally target conserved regions of the parasite or elicit broad immunity to remain effective against evolving strains.^[47]

Historical Context of Malaria Vaccines

Early Research

Initial efforts in malaria vaccine research date back to the 1960s. Studies demonstrated that exposing mice to irradiated sporozoites of Plasmodium berghei could induce protective immunity. Subsequent human trials in the 1970s showed similar protective effects against P. vivax and P. falciparum through exposure to irradiated mosquitoes.^[60]^[61]

Key Milestones

The SPf66 vaccine, a synthetic peptide-based candidate developed in Colombia, showed limited efficacy in trials during the 1990s.^[43] The development of RTS,S marked a significant breakthrough, culminating in its WHO endorsement in 2021 after extensive trials and pilot programs.^[21] The subsequent endorsement of R21/Matrix-M further advances the field.^[8]

Emerging Vaccine Candidates

PfSPZ Vaccine

Developed by Sanaria, the PfSPZ vaccine uses radiation-attenuated sporozoites. Clinical trials have shown promising protection rates, with over 80% of volunteers protected in studies across Africa, Europe, and the US. Challenges include large-scale production and the requirement for ultra-cold storage.^[40]

Other Research Avenues

Ongoing research explores various targets and platforms. Nanoparticle-based vaccines, viral vector vaccines targeting PfRH5, and vaccines targeting protein kinases are among the diverse approaches being investigated. The development of a second-generation vaccine combining pre-erythrocytic and blood-stage antigens, such as RH5.1/Matrix-M, aims for even higher efficacy.^[33]

Teacher's Corner

Edit and Print this course in the Wiki2Web Teacher Studio

Edit and Print Materials from this study in the wiki2web studio

Click here to open the "Malaria Vaccine" Wiki2Web Studio curriculum kit

Use the free Wiki2web Studio to generate printable flashcards, worksheets, exams, and export your materials as a web page or an interactive game.

True or False?

Test Your Knowledge!

Gamer's Corner

Are you ready for the Wiki2Web Clarity Challenge?

Learn about malaria_vaccine while playing the wiki2web Clarity Challenge game.

Unlock the mystery image and prove your knowledge by earning trophies. This simple game is addictively fun and is a great way to learn!

Play now

Explore More Topics

Discover other topics to study!

populism

syrian arab armed forces

henry iii of england

saturday ocean colour scene album

gaza–jericho agreement

list of ufc encyclopedia award recipients

post-soviet states

forbes

honey bee

grodno state medical university

References

A full list of references for this article are available at the Malaria vaccine Wikipedia page

Feedback & Support

To report an issue with this page, or to find out ways to support the mission, please click here.

Important Considerations

Medical Advice Disclaimer

This content is generated by Artificial Intelligence for educational and informational purposes only. It is based on publicly available data and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment. Reliance on any information provided herein is solely at your own risk.

The information presented here is not intended to replace consultation with medical professionals.

Malaria Vaccine: A Scientific Expedition

💡 Dive in with Flashcard Learning! 💡

Understanding Malaria Vaccines ℹ️

🌍 Global Health Imperative

💉 The Goal of Immunization

📜 Essential Medicine Status

Approved Malaria Vaccines ✅

🌟 RTS,S/Mosquirix

🚀 R21/Matrix-M

Deep Dive: RTS,S/Mosquirix 🔬

🧬 Mechanism of Action

📊 Clinical Trial Outcomes

🌍 Deployment and Impact

Focus: R21/Matrix-M 🔬

💡 Advanced Efficacy

📈 Promising Trial Data

🏭 Manufacturing and Approval

Vaccine Development Strategies ⚙️

🧩 Targeting the Parasite Lifecycle

🔬 Key Antigens and Approaches

🛡️ Challenges: Parasite Diversity and Resistance

Historical Context of Malaria Vaccines ⏳

📜 Early Research

🔬 Key Milestones

Emerging Vaccine Candidates 💡

🔬 PfSPZ Vaccine

🧪 Other Research Avenues

Teacher's Corner 🧑‍🏫

Edit and Print this course in the Wiki2Web Teacher Studio

True or False? 🤔

❓ Test Your Knowledge! ❓

Gamer's Corner 🎮

Are you ready for the Wiki2Web Clarity Challenge?

Explore More Topics

📜 Discover other topics to study!

References

📜 References

Feedback & Support 👍

To report an issue with this page, or to find out ways to support the mission, please click here.

Important Considerations ⚠️

📜 Medical Advice Disclaimer

Dive in with Flashcard Learning!

Understanding Malaria Vaccines

Global Health Imperative

The Goal of Immunization

Essential Medicine Status

Approved Malaria Vaccines

RTS,S/Mosquirix

R21/Matrix-M

Deep Dive: RTS,S/Mosquirix

Mechanism of Action

Clinical Trial Outcomes

Deployment and Impact

Focus: R21/Matrix-M

Advanced Efficacy

Promising Trial Data

Manufacturing and Approval

Vaccine Development Strategies

Targeting the Parasite Lifecycle

Key Antigens and Approaches

Challenges: Parasite Diversity and Resistance

Historical Context of Malaria Vaccines

Early Research

Key Milestones

Emerging Vaccine Candidates

PfSPZ Vaccine

Other Research Avenues

Teacher's Corner

True or False?

Test Your Knowledge!

Gamer's Corner

Discover other topics to study!

References

Feedback & Support

Important Considerations

Medical Advice Disclaimer